Zevra Therapeutics, Inc. (ZVRA)
NASDAQ·Healthcare·Biotechnology
$9.95
+1.43%
Mkt Cap $595.88M
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Mar 9, 2026 | $28.05M | $34.10M | +21.56% | $0.05 | $1.16 | +2201.59% | — | — |
| Q4 2025 Nov 5, 2025 | $26.64M | $26.06M | -2.17% | -$0.02 | -$0.01 | +50.00% | — | — |
| Q3 2025 Aug 12, 2025 | $24.52M | $25.88M | +5.56% | $2.19 | $1.21 | -44.75% | — | — |
| Q2 2025 May 13, 2025 | $21.07M | $20.40M | -3.19% | -$0.21 | -$0.06 | +71.43% | — | — |
| Q1 2025 Mar 11, 2025 | $16.66M | $12.04M | -27.73% | -$0.39 | -$0.67 | -71.79% | — | — |
| Q4 2024 Nov 12, 2024 | $8.78M | $3.69M | -57.90% | -$0.44 | -$0.69 | -56.82% | — | — |
| Q3 2024 Aug 13, 2024 | $4.36M | $4.45M | +2.04% | -$0.47 | -$0.48 | -2.13% | — | — |
| Q2 2024 May 8, 2024 | $4.65M | $3.42M | -26.34% | -$0.49 | -$0.40 | +18.37% | — | — |
| Q1 2024 Mar 28, 2024 | $11.74M | $13.22M | +12.58% | -$0.20 | -$0.40 | -100.00% | — | — |
| Q4 2023 Nov 7, 2023 | $10.95M | $2.90M | -73.56% | -$0.29 | -$0.40 | -37.93% | — | — |
| Q3 2023 Aug 14, 2023 | $3.03M | $8.47M | +179.54% | -$0.39 | -$0.15 | +61.54% | — | — |
| Q2 2023 May 15, 2023 | $2.65M | $2.88M | +8.64% | -$0.26 | -$0.34 | -30.77% | — | — |
| Q1 2023 Mar 7, 2023 | $3.11M | $2.32M | -25.34% | -$0.21 | -$0.26 | -23.81% | — | — |
| Q4 2022 Nov 9, 2022 | $3.01M | $2.87M | -4.59% | -$0.13 | -$0.19 | -46.15% | — | — |
| Q3 2022 Aug 11, 2022 | $1.75M | $1.30M | -25.61% | -$0.12 | -$0.19 | -58.33% | — | — |
| Q2 2022 May 12, 2022 | $3.06M | $3.96M | +29.36% | -$0.05 | -$0.05 | +0.00% | — | — |
| Q1 2022 Mar 30, 2022 | $2.23M | $2.58M | +15.53% | -$0.07 | -$0.08 | -14.29% | — | — |
| Q4 2021 Nov 10, 2021 | — | $1.97M | — | -$0.07 | -$0.05 | +28.57% | — | — |
| Q3 2021 Aug 12, 2021 | — | $11.99M | — | $0.23 | $0.21 | -8.70% | — | — |
| Q2 2021 May 13, 2021 | — | $12.12M | — | -$0.17 | -$0.54 | -217.65% | — | — |